FTSE 100 movers: Barclays buoyant while drugmakers sink

Barclays got a lift after Exane BNP Paribas upgraded the stock to ‘outperform’ from ‘neutral’ as it took a look at UK banks.

Shire was under the cosh as part of a sector-wide decline even as it posted interim numbers that showed total reported product sales up 36% to $3.9bn in the six months to 30 June.

Broker Liberum said "some are worried about patent litigation over the next quarter".

Product sales improved at double-digit rates across all of Shire’s legacy business, with genetic diseases up 14% to $1.3bn, neuroscience up 19% to $1.3bn, and internal medicine up 18% to $0.8bn.

Earnings before interest, tax, depreciation and amortisation rose 35% on the previous year to $1.9bn.

Chief executive Flemming Ornskov said the closing of the Baxalta acquisition at the start of June was the "capstone" of the first half of the year, but it would be remiss to overlook the acquisition of Dyax in January, which brought on board some exciting pre-revenue drugs.

Other drugmakers in the losing column included Hikma Pharmaceuticals, GlaxoSmithKline and AstraZeneca.

FTSE 100 - Risers

Barclays (BARC) 156.70p 3.09%
Antofagasta (ANTO) 528.00p 2.72%
Royal Bank of Scotland Group (RBS) 182.80p 2.58%
BHP Billiton (BLT) 1,038.00p 2.37%
Provident Financial (PFG) 2,807.00p 2.26%
Sainsbury (J) (SBRY) 234.80p 2.13%
Lloyds Banking Group (LLOY) 54.26p 2.09%
Capita (CPI) 973.50p 1.88%
Marks & Spencer Group (MKS) 327.60p 1.87%
Prudential (PRU) 1,400.50p 1.67%

FTSE 100 - Fallers

Hikma Pharmaceuticals (HIK) 2,294.00p -4.22%
British American Tobacco (BATS) 4,745.00p -1.79%
Shire Plc (SHP) 5,060.00p -1.65%
GlaxoSmithKline (GSK) 1,672.50p -1.30%
AstraZeneca (AZN) 5,155.00p -1.25%
Compass Group (CPG) 1,449.00p -1.23%
United Utilities Group (UU.) 976.00p -1.11%
Relx plc (REL) 1,416.00p -1.05%
Diageo (DGE) 2,160.50p -0.89%
Unilever (ULVR) 3,510.50p -0.88%